Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19

Autor: Xiaojun Meng, Hudan Pan, Xi Huang, Qingqin Tan, Lingjie He, Wei Wang, Hong Shan, Tianchuan Zhu, Weiguo Yin
Jazyk: angličtina
Rok vydání: 2021
Předmět:
medicine.drug_class
Biomedical Engineering
Anti-Inflammatory Agents
Pharmaceutical Science
Medicine (miscellaneous)
Bioengineering
Inflammation
Pharmacology
Applied Microbiology and Biotechnology
Antiviral Agents
Proinflammatory cytokine
03 medical and health sciences
0302 clinical medicine
Biomimetics
Anti-inflammation
medicine
Medical technology
Macrophage
Humans
R855-855.5
030304 developmental biology
0303 health sciences
Drug Carriers
business.industry
SARS-CoV-2
Research
technology
industry
and agriculture
COVID-19
medicine.disease
COVID-19 Drug Treatment
Cytokine storm syndrome
Antiviral treatment
030220 oncology & carcinogenesis
Drug delivery
Molecular Medicine
Biomimetic nanocarriers
Nanoparticles
Nanocarriers
Antiviral drug
medicine.symptom
Drug carrier
Cytokine storm
business
Cytokine Release Syndrome
TP248.13-248.65
Biotechnology
Zdroj: Journal of Nanobiotechnology
Journal of Nanobiotechnology, Vol 19, Iss 1, Pp 1-16 (2021)
ISSN: 1477-3155
Popis: Background The worldwide pandemic of COVID-19 remains a serious public health menace as the lack of efficacious treatments. Cytokine storm syndrome (CSS) characterized with elevated inflammation and multi-organs failure is closely correlated with the bad outcome of COVID-19. Hence, inhibit the process of CSS by controlling excessive inflammation is considered one of the most promising ways for COVID-19 treatment. Results Here, we developed a biomimetic nanocarrier based drug delivery system against COVID-19 via anti-inflammation and antiviral treatment simultaneously. Firstly, lopinavir (LPV) as model antiviral drug was loaded in the polymeric nanoparticles (PLGA-LPV NPs). Afterwards, macrophage membranes were coated on the PLGA-LPV NPs to constitute drugs loaded macrophage biomimetic nanocarriers (PLGA-LPV@M). In the study, PLGA-LPV@M could neutralize multiple proinflammatory cytokines and effectively suppress the activation of macrophages and neutrophils. Furthermore, the formation of NETs induced by COVID-19 patients serum could be reduced by PLGA-LPV@M as well. In a mouse model of coronavirus infection, PLGA-LPV@M exhibited significant targeted ability to inflammation sites, and superior therapeutic efficacy in inflammation alleviation and tissues viral loads reduction. Conclusion Collectively, such macrophage biomimetic nanocarriers based drug delivery system showed favorable anti-inflammation and targeted antiviral effects, which may possess a comprehensive therapeutic value in COVID-19 treatment.
Databáze: OpenAIRE
Externí odkaz: